For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | - | 2,733,000 | 57,000 | 56,000 |
| Research and development | 2,311,000 | 2,291,000 | 2,506,000 | 1,885,000 |
| Acquired in-process research and development | - | - | - | 0 |
| General and administrative | 1,744,000 | 1,691,000 | 2,754,000 | 3,416,000 |
| Total operating expenses | 4,055,000 | 3,982,000 | 5,260,000 | 5,301,000 |
| Loss from operations | -4,055,000 | -1,249,000 | -5,203,000 | -5,245,000 |
| Change in fair value of warrant liability | 3,000 | -146,000 | -26,513,000 | 6,109,500 |
| Other income, net | 96,000 | 188,000 | 180,000 | 11,500 |
| Net (loss) income | -3,962,000 | -915,000 | 21,490,000 | -17,452,500 |
| Net (loss) income attributable to series c preferred stockholders, basic | - | -290,000 | 6,407,000 | -27,962,250 |
| Net (loss) income attributable to common stockholders, basic | -3,035,000 | -625,000 | 15,083,000 | -13,668,500 |
| Earnings per share, basic | -0.34 | -0.11 | 2.17 | -10.765 |
| Earnings per share, diluted | -0.34 | -0.11 | 2.09 | -10.765 |
| Weighted average number of shares outstanding, basic | 8,818,859 | 5,820,903 | 6,965,927 | -12,359,809.5 |
| Weighted average number of shares outstanding, diluted | 8,818,859 | 5,820,903 | 7,215,125 | -12,359,809.5 |
Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc. (TRAW)